Alpha&Szenszor& · enoseSensorCompe.on+ Au Nano-particles, Si Nanowire Metal Oxide Semiconduct ors...
Transcript of Alpha&Szenszor& · enoseSensorCompe.on+ Au Nano-particles, Si Nanowire Metal Oxide Semiconduct ors...
Alpha Szenszor Non-‐Invasive Diagnos.c Sensors
Steve Lerner Founder/CEO [email protected] +1 978 371 7084 www.alphaszenszor.com
ASI Confiden.al
Highlights
• Alpha Szenszor Inc. provides an agnostic e-nose sensor platform based on proprietary CMOS compatible Carbon
Nanotube Technology, licensed exclusively though Nantero
• The Company has recently formed a JV with the Technion in Israel called ‘Alnion’, addressing early stage cancer diagnostics through the emerging field of volatilomics
http://youtu.be/3l5e11B5xYI • IEEE and Wall Street Journal ranking of IP in top 2 WW
• Well suited for applications in medical diagnostics, wearables, environmental health monitoring and safety
ASI Confiden.al
ASI’s Annual Sensor Chip TAM
Cancer
Personal Exposure Monitor
Renal Disease
Capnography
Asthma & COPD
Wearables
ASI CNT Sensor
3
Substance Abuse
80 BILLION
chips
570 MILLION
Chips
300 MILLION
Chips
Non Invasive Diabetes
3 BILLION Chips
3 BILLION Chips
1.2 BILLION Chips
56.2 MILLION
Chips
ASI Confiden.al
Team
Dr. Sarbajit Banerjee, PhD
Texas A&M, Chemistry
Dr. Brent M. Segal, PhD Lockheed Mar.n, Nanotechnology
Prof. Hossam Haick, PhD, Prof. Chemistry Technion – Israel (Marie Curie Excellence Award, ERC Award etc.)
Dr. Jean-‐Frédéric Sauniere, MD, PhD
Ins.tut Paoli & Calme\es
Dr. Nir Peled, MD, PhD, FCCP Sheba Medical Center
Steve Lerner, CEO 30+ years of Disrup.ve Innova.on in Microelectronics and Materials. Startups, IPO, M&A
Dr. Prashanth Makaram PhD, VP Process Development 10 years in electronic materials, Nanotechnology
Dr. Claudio Truzzi PhD, VP System Design 25 years in microelectronics and materials technologies
Management Team
Advisory Board
ASI Confiden.al
The Nanoscale & CNTs
Source: Shellzero.wordpress.com
Carbon Nanotubes • Strongest organic
material: 5X stronger than steel
• Near ballistic transport in metallic
• Semiconducting CNTs have high ON-OFF ratio (~105)
• Optimum size for detection of small concentrations of molecules
• Selective to specific compounds when chemically programmed
ASI Confiden.al
e-‐nose Sensor Compe..on
Au Nano-particles, Si Nanowire
Metal Oxide Semiconductors (MOS)
Quartz Crystal Microbalance (QCM)
Colorimetric Sensor
Conductive Polymers (CP)
Gas Chromotography/ Mass Spec. (GC/MS)
Alpha SZENSZOR
(CNTs)
Sampling Non-Invasive Non-invasive Non-invasive Non-invasive Non-invasive Non-Invasive
Non-invasive
Sensitivity High (ppb) Moderate- High (sub-ppm)
Moderate (ppm)
Hign (ppb-ppm)
Moderate-high (sub-ppm)
High (ppb) High (ppb)
Power Consumption
High High High Moderate Moderate Very High Very Low
Speed Fast Moderate Moderate (~ 1 min)
Fast Fast Slow (~30 mins)
Very Fast (<30 sec)
Ease of Use Easy, no training required
Easy, no training required
Easy, no training required
Easy, no training required
Easy Needs specialized training
Easy, no specific skills required
Cost low Moderate Moderate Moderate low Very High low
Portability Yes Yes Yes No Yes No Yes
Deployment Limitations
• Poor yielding process, bad batch reproducibility • Hi power requirements
• High operating temperature • high power requirement • Not suitable for VOC detection.
• Low Signal to Noise ratios • Complex fabrication and circuitry • bad batch reproducibility
• Requires sophisticated optics • sensor cannot be reused • Non-specific for sub-histologies
• Affected by humidity • sensor overload • limited lifetime
• Affected by background noise and moisture • Complex • Nonspecific for sub-histologies
None Proven to be a Fab friendly, scalable production process
ASI Confiden.al
E-‐nose Pa\ern Analysis Theory
• The expression "electronic sensing" refers to the capability of reproducing human senses using sensor arrays and a paWern recogniXon system
• Several known and tested pa\ern recogni.on algorithms exists and has been extensively used for facial recogni.on, finger print analysis, and electronic nose sensor applica.ons for fruit odors, food spoilage etc.
Pearce, Tim C., et al., eds. Handbook of machine olfac0on. Wiley. com, 2006.
ASI Confiden.al
Specificity Techniques
• CNT Surface Func.onaliza.on:
1. Metal nano par.cles 2. DNA 3. Polymers
• Extrac.on of Descriptors: 1. Resistance Varia.on 2. Deriva.ve 3. Integral 4. Resistance Minimum 5. Ra.o between reference and
minimum reference value
1
2
3
4
ASI Confiden.al
What are the markets saying ? • “Dogs can do it but machines hold the best hopes
for earlier detec0on” – Cosmo Magazine
• “In 5 years computers will have a sense of smell…. By capturing the informa0on they carry, technology can pick up clues about your health and provide valuable diagnos0c informa0on to your physician.”
– Dr. Hendrik F. Hamann, IBM Research (2012)
• Alnion Ranked #1 in “Top 10 Israeli medical
advances to watch in 2014”. – Israel21C
ASI Confiden.al
High End App – Lung Cancer
SensiXvity Specificity Accuracy ROC AUC
Malignant/ Benign 86±5% 93±7% 88±2% 0.986
Adeno/squamous 92±8% 78±7% 88±3% 0.974
Early/Advanced NSCLC 86±3% 88±6% 88±2% 0.961
Peled, N.; Hakim, M.; Tisch, U.; Bunn, P. A. Jr. R.; Miller, Y. E.; Kennedy, T. C.; Ma\ei, J.; Mitchell, J. D.; Weyant, M. J.; Hirsch, F. R.; Haick, H.* J. Thorac. Oncol. 7(10), 1528-‐1533 (2012)
Training set: 75% of the samples.
Test (blind) set: 25% of the samples
ASI Confiden.al
Mid Range App -‐ Diabetes
Carbon Nanotube Sensor
Standard Test Strip Format Glucometer Smartphone or Watch APP management
S Glucose present in Saliva correlates with tradi.onally monitored blood glucose levels.
S Mul.ple study groups around the world have demonstrated the u.lity of using saliva for diabetes monitoring.
S Glucose concentra.ons in saliva are 100 .mes less than those in blood and require a highly sensi.ve device such as ASI’s carbon nanotube sensor for accurate detec.on.
ASI Confiden.al
Recent references to the Literature
Test showing correla.on of serum and salivary glucose level. Abikshyeet et. al. " Diabetes, metabolic syndrome and obesity: targets and therapy 5 (2012): 149.
Carbon Nanotube Sensor Detects Glucose in Saliva, MIT Tech Review, Apr 30, 2013
ASI Confiden.al
Low End App -‐ Wearables Fabulyzer measures Acetone in Breath to monitor Fat Burn -‐ Break down enough fat and eventually this compound will find its way into your breath,
-‐ so when you blow onto the fat-‐burning breathalyzer, you’ll know if you’re doing enough exercise to shed off those extra pounds or not.
ASI Confiden.al
Trend in Breathalyzers Today
(Non-‐Wearable SoluXons)
Kisai Breathalyzer
Tomorrow (Wearable SoluXons)
Breathometer (Alcohol breathalyzer) Raised $2M in 2013
NTT Docomo Fat burner ASI Confiden.al
ASI Appliance Feasibility
CNT Fabric Field
S D
The core technology is
based on proprietary
Carbon Nanotube IP
and Know-how
CNT sensor arrays are
manufactured and chemically programmed in
standard electronics
manufacturing environments
Low cost consumer electronics
mother board consolidates all
functions
Final appliance with wireless connection to commercially available PC, smart phone, etc.,
loaded with PRS algorithms or
downloaded from cloud
ASI Confiden.al
Personalized Screening & Monitoring
o Personal breath-‐print in the cloud
o Periodic monitoring & storing
o Trend tracking of pa.ent’s health progression/deteriora.on
o Early interven.on
o Tracking response to therapeu.cs
o Follow-‐up auer surgery
o Gene.c muta.ons
Comprehensive disease management
Pa.ent
Breath Cloud
(database)
Age
gender
ethnicity Smoking habits
Medica.on
Confound-‐ing factors
ASI E-‐Nose Medical Staff
Breath
ASI Confiden.al
ASI is currently seeking the Following:
A) Direct Investment in the Company, ~€2M To build out generic chip manufacturing capability
– The Netherlands?
B) JV’s or Industrial partnerships to address new applica.ons
• Typical prototype program ~ €500K (Demonstrator with ISO 13485 compliant specs.)
• €3M – €5M Investment to commercialize stand alone business model: -‐ full product development & qualifica.on
ASI Confiden.al
Summary
• Full Range of Non-‐Invasive Diagnos.c Tes.ng
• Dominant IP, as ranked by IEEE and The WSJ
• Demonstrated Field Data through Leading Hospitals
• Leads All Compe..on as a non-‐invasive, highly sensi.ve, scalable, yet cost effec.ve plaxorm technology
• Rapid .me to market: 1-‐2 yrs Consumer, 2-‐ 3 yrs Medical
• Fully Compa.ble with Current Manufacturing Supply Chains
ASI Confiden.al